文献速递产科母胎医学

阴道孕酮降低双胎妊娠伴宫颈缩短妇女的早产及新生儿疾病和死亡:个体患者数据更新Meta分析

Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data.
PubMed 文献 · Ultrasound Obstet Gynecol · 2017-01-01

本更新个体患者数据Meta分析纳入6项随机对照试验的303名无症状双胎妊娠且孕中期宫颈长度≤25mm妇女及其606名胎儿/婴儿,比较阴道孕酮与安慰剂/无治疗。阴道孕酮组早产<33周风险显著低于对照组(31.4% vs 43.1%;RR 0.69,95%CI 0.51-0.93;中等质量证据),并降低新生儿死亡、呼吸窘迫综合征等风险,4-5岁神经发育结局无显著差异。

要点

  • 双胎妊娠伴孕中期宫颈长度≤25mm的无症状妇女,阴道孕酮降低<33周早产风险(31.4% vs 43.1%;RR 0.69)。
  • 阴道孕酮降低新生儿死亡(RR 0.53)、呼吸窘迫综合征(RR 0.70)及复合新生儿疾病和死亡(RR 0.61)。
  • 4-5岁神经发育结局在阴道孕酮组与安慰剂组间无显著差异。

核心结论

  • 对双胎妊娠伴孕中期超声宫颈缩短的无症状妇女给予阴道孕酮,可降低<30至<35孕周早产风险、新生儿死亡及部分新生儿疾病指标,且未显示对儿童神经发育的有害影响。

研究设计与样本

  • 更新系统综述与个体患者数据Meta分析,纳入6项比较阴道孕酮与安慰剂/无治疗的随机对照试验,共303名妇女(阴道孕酮组159名,安慰剂/无治疗组144名)及其606名胎儿/婴儿。
  • 检索MEDLINE、EMBASE、POPLINE、CINAHL和LILACS(均从建库至2016年12月31日)、Cochrane对照试验中心注册库、进行中试验研究注册库、Google Scholar、会议论文集及已识别研究的参考文献列表。
  • 主要结局为<33孕周早产,计算合并相对危险度(RR)及95%置信区间(CI)。

主要发现

  • 阴道孕酮组与安慰剂/无治疗组比较,<33孕周早产风险为31.4% vs 43.1%(RR 0.69,95%CI 0.51-0.93;中等质量证据)。
  • 阴道孕酮组<35、<34、<32和<30孕周早产风险均显著降低(RR范围0.47至0.83;中等质量证据)。
  • 阴道孕酮组新生儿死亡风险RR 0.53(95%CI 0.35-0.81),呼吸窘迫综合征风险RR 0.70(95%CI 0.56-0.89),复合新生儿疾病和死亡风险RR 0.61(95%CI 0.34-0.98),使用机械通气风险RR 0.54(95%CI 0.36-0.81),出生体重<1500g风险RR 0.53(95%CI 0.35-0.80)(均为中等质量证据)。
  • 阴道孕酮组与安慰剂组在4-5岁神经发育结局方面无显著差异。

关键数值与推荐

  • 纳入标准:无症状双胎妊娠妇女,孕中期超声宫颈长度≤25mm。
  • 主要结局<33孕周早产:阴道孕酮组31.4% vs 安慰剂/无治疗组43.1%(RR 0.69,95%CI 0.51-0.93;中等质量证据)。
  • 新生儿死亡RR 0.53(95%CI 0.35-0.81);呼吸窘迫综合征RR 0.70(95%CI 0.56-0.89);复合新生儿疾病和死亡RR 0.61(95%CI 0.34-0.98);机械通气RR 0.54(95%CI 0.36-0.81);出生体重<1500g RR 0.53(95%CI 0.35-0.80)(均为中等质量证据)。

临床怎么用

  • 原文结论为对双胎妊娠伴孕中期超声宫颈缩短的无症状妇女给予阴道孕酮可降低早产及新生儿不良结局风险,未给出具体用药方案或推荐等级。

局限性

  • 一项纳入宫颈长度20至25mm妇女的研究提供了个体患者数据Meta分析总样本量的74%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy of vaginal progesterone for the prevention of preterm birth and neonatal morbidity and mortality in asymptomatic women with a twin gestation and a sonographic short cervix (cervical length ≤ 25 mm) in the mid-trimester. METHODS: This was an updated systematic review and meta-analysis of individual patient data (IPD) from randomized controlled trials comparing vaginal progesterone with placebo/no treatment in women with a twin gestation and a mid-trimester sonographic cervical length ≤ 25 mm. MEDLINE, EMBASE, POPLINE, CINAHL and LILACS (all from inception to 31 December 2016), the Cochrane Central Register of Controlled Trials, Research Registers of ongoing trials, Google Scholar, conference proceedings and reference lists of identified studies were searched. The primary outcome measure was preterm birth < 33 weeks' gestation. Two reviewers independently selected studies, assessed the risk of bias and extracted the data. Pooled relative risks (RRs) with 95% confidence intervals (CI) were calculated. RESULTS: IPD were available for 303 women (159 assigned to vaginal progesterone and 144 assigned to placebo/no treatment) and their 606 fetuses/infants from six randomized controlled trials. One study, which included women with a cervical length between 20 and 25 mm, provided 74% of the total sample size of the IPD meta-analysis. Vaginal progesterone, compared with placebo/no treatment, was associated with a statistically significant reduction in the risk of preterm birth < 33 weeks' gestation (31.4% vs 43.1%; RR, 0.69 (95% CI, 0.51-0.93); moderate-quality evidence). Moreover, vaginal progesterone administration was associated with a significant decrease in the risk of preterm birth < 35, < 34, < 32 and < 30 weeks' gestation (RRs ranging from 0.47 to 0.83), neonatal death (RR, 0.53 (95% CI, 0.35-0.81)), respiratory distress syndrome (RR, 0.70 (95% CI, 0.56-0.89)), composite neonatal morbidity and mortality (RR, 0.61 (95% CI, 0.34-0.98)), use of mechanical ventilation (RR, 0.54 (95% CI, 0.36-0.81)) and birth weight < 1500 g (RR, 0.53 (95% CI, 0.35-0.80)) (all moderate-quality evidence). There were no significant differences in neurodevelopmental outcomes at 4-5 years of age between the vaginal progesterone and placebo groups. CONCLUSION: Administration of vaginal progesterone to asymptomatic women with a twin gestation and a sonographic short cervix in the mid-trimester reduces the risk of preterm birth occurring at < 30 to < 35 gestational weeks, neonatal mortality and some measures of neonatal morbidity, without any demonstrable deleterious effects on childhood neurodevelopment. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Romero R, Conde-Agudelo A, El-Refaie W, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 2017. PMID: 28067007. doi:10.1002/uog.17397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。